German gov’t deals blow to Sanofi-Aventis’ Acomplia

Share this article:
Sanofi-Aventis said it intends to contest in court the decision by the German health ministry to classify anti-obesity drug Acomplia as a non-reimbursable drug. The ministry recommendation was published in the Official Journal of the Government, prompting an immediate response by the drug maker. “Sanofi-Aventis considers the proposed reimbursement classification of Acomplia as unjustified given the profile of the drug,” the firm said in a statement. Sanofi has argued that, since it helps lower a person's risk for developing diabetes and heart disease in addition to helping with weight loss, rimonabant should be covered under the state health insurance program.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions